HCW Biologics Inc is trading at $1.12 (8.2% down) after shareholders approved a reverse stock split and warrant-related share issuance at the June 15 annual meeting.
- The approved measures are intended to help the company maintain its Nasdaq listing requirements and facilitate a recent warrant offering.
- The stock has experienced significant volatility, with the current decline reflecting investor concerns regarding potential share dilution and capital structure changes.